Previous 10 | Next 10 |
2024-05-03 06:02:55 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Amneal Pharmaceuticals Q1 2024 Earnings Preview FDA approves...
‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement...
2024-05-02 11:48:35 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation FDA approves Amneal's generic version of OTC Narcan Bausch H...
2024-04-26 17:00:42 ET Gainers: Heartland Financial USA ( HTLF ) +9% . Accolade ( ACCD ) +6% . Editas Medicine ( EDIT ) +4% . Nextracker ( NXT ) +3% . Clean Energy Fuels ( CLNE ) +2% . Losers: Vitru ( VTRU ) -...
2024-04-24 11:01:15 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health sues Amneal Pharma over Xifaxan generic Amneal...
Company launches generic equivalent to OTC NARCAN ® Nasal Spray Provides convenient, affordable access to life-saving medicine Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the availability of Over th...
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forw...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. Th...
2024-04-08 15:32:37 ET More on Bausch Health Companies Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation Bausch Health Companies (BHC) Q4 2023 Earnings Call Transcript Bausch Health sues Amneal Pharma over Xifaxan generic Bausch Health Com...
2024-04-06 09:26:54 ET More on Amneal, Bausch Health, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health: A Timely Divestiture Is The Key To An Higher Val...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a Leading Provider of Accessible Medicines Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Companyȁ...
The Company’s leading R&D capabilities and robust, expanded manufacturing capacity are helping to address chronic market shortages Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of it...
Significantly expanding access to affordable, life-saving opioid overdose rescue medicine Entered distribution agreement with California; actively engaging with other states and municipalities to expand access Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” o...